Home/Pipeline/VIAL-INHBE (siRNA)

VIAL-INHBE (siRNA)

Obesity

Phase 1Active

Key Facts

Indication

Obesity

Phase

Phase 1

Status

Active

Company

VIAL Dermatology CRO

About VIAL Dermatology CRO

VIAL is a private, pre-revenue biotech company pioneering a tech-enabled approach to drug discovery and development. Its core strategy integrates computational target discovery, AI-driven molecule design (for antibodies, siRNA, and small molecules), and an automated clinical trial platform to increase speed and scalability. The company's initial pipeline features two Phase 1-ready assets in immunology and metabolic disease, positioning it to address significant unmet needs in large markets like atopic dermatitis, asthma, and obesity.

View full company profile

Therapeutic Areas

Immunology Dermatology Metabolic Disease

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
RGT-075	Regor Therapeutics	Phase 2b	Active
Anti‑Obesity Oral Drug	Premas Biotech	Phase 1	Active
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active